General MedicationsINTRAVENOUSGeneric
BORTEZOMIB
BORTEZOMIB
Standard Dose
3.5MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview BORTEZOMIB is listed in Drugs@FDA under application 206927 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient BORTEZOMIB Form and strength POWDER;INTRAVENOUS - 3.5MG/VIAL Sponsor DR REDDYS Submission history Latest submission status date: 2022-02-28 00:00:00.
Structured Monograph
Clinical summary
Approval overview BORTEZOMIB is listed in Drugs@FDA under application 206927 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient BORTEZOMIB Form and strength POWDER;INTRAVENOUS - 3.5MG/VIAL Sponsor DR REDDYS Submission history Latest submission status date: 2022-02-28 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.